Related Experiment Video
Updated: May 26, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease
Warisara Panawong1, Aporanee Chaiyakum, Cholatip Pongskul
1Division of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand. wpanawong@hotmail.co.th
Insights
Adherence to mineral and bone disorder guidelines in chronic kidney disease patients was high for calcium and phosphate monitoring but low for PTH monitoring and vitamin D3 use. Achieving PTH targets remains a challenge.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Medicine
Background:
- Mineral and bone disorders (MBD) are significant cardiovascular risk factors in chronic kidney disease (CKD) patients.
- Clinical practice guidelines (CPG) aim to prevent MBD and reduce cardiovascular events in CKD.
Purpose of the Study:
- To assess adherence to MBD-CPG in CKD patients.
- Evaluate the achievement of K/DOQI 2003 target recommendations.
Main Methods:
- Retrospective observational study of 206 CKD patients (stages 3-5).
- Data collected from pre-dialysis and dialysis clinics between July and September 2007.
Main Results:
- High adherence for calcium (89.5%) and phosphate (88.6%) monitoring.
- Low adherence for PTH monitoring (17.1%) and vitamin D3 use (72.2%).
- Significant positive impact of phosphate binder adherence on calcium, phosphate, and CaxP product achievement.
Conclusions:
- Adherence to vitamin D3 use, PTH monitoring, and PTH target achievement requires improvement.
- Long-term studies are needed to investigate therapeutic endpoints for cardiovascular and bone diseases in CKD.
Background:
Mineral and bone disorders (MBD) in patients with chronic kidney disease (CKD) are cardiovascular risk factors. Clinical practice guidelines were developed to prevent MBD and to decrease cardiovascular events in CKD patients.
Objective:
To determine adherence to mineral and bone disorder clinical practice guidelines (MBD-CPG) in chronic kidney disease patients.
Material And Method:
A retrospective, observational study was performed on 206 patients with CKD stage 3, 4, and 5 that were followed-up at pre-dialysis and dialysis clinic, Nephrology Unit, Srinagarind Hospital between July and September 2007.
Results:
The mean percentages of adherence in each patient were 89.5% for calcium monitoring, 88.6% for phosphate monitoring and 17.1% for PTH monitoring. The mean percentage of adherence to using of phosphate binder in each patient was 84.6%. The mean percentage of adherence to using of vitamin D3 was 72.2% in patients who had all three clinical parameters monitoring. The K/DOQI 2003 target recommendation achievements at the end of study were 73.7% for serum calcium, 76.1% for serum phosphate, 94.6% for calculated CaxP product, and 23.7% for serum PTH. The mean percentage of K/DOQI 2003 target recommendation achievement, in each patient during 12 months of postindex period, were: 79.3% for serum calcium, 78.1% for serum phosphate, 95.8% for serum CaxP product and 26.3% for serum PTH. The 100% achievement of target recommendations for serum calcium, serum phosphate and serum CaxP product were statistically, significant different, when compared between the group of 100% and 75.0-99.9% adherence to using phosphate binder, with the odd ratio 5.43 (95% CI 2.43-12.11) for serum calcium achievement, 11.33 (95% CI 4.63-27.72) for serum phosphate achievement and 11.75 (95% CI 2.92-47.24) for CaxP product achievement.
Conclusion:
The use of vitamin D3, monitoring of serum PTH and achieving of PTH target level, are still far from recommendations. Therapeutic end point for cardiovascular and bone diseases should be investigated in long-term studies.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease I: Introduction
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
